MoonLake Immunotherapeutics Files Definitive Proxy Statement
Ticker: MLTX · Form: DEF 14A · Filed: Apr 22, 2025 · CIK: 1821586
| Field | Detail |
|---|---|
| Company | Moonlake Immunotherapeutics (MLTX) |
| Form Type | DEF 14A |
| Filed Date | Apr 22, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
MoonLake Immunotherapeutics filed its proxy statement for the June 5th shareholder meeting. Standard procedure.
AI Summary
MoonLake Immunotherapeutics filed a definitive proxy statement (DEF 14A) on April 22, 2025, for its annual meeting on June 5, 2025. The company, formerly known as Helix Acquisition Corp, is in the pharmaceutical preparations industry. This filing is a standard procedural document for shareholder voting.
Why It Matters
This filing provides shareholders with the necessary information to vote on company matters at the upcoming annual meeting, impacting corporate governance and strategic decisions.
Risk Assessment
Risk Level: low — This filing is a routine proxy statement and does not contain new material financial or operational information that would inherently increase risk.
Key Numbers
- 20250605 — Annual Meeting Date (Shareholders will vote on company matters.)
- 20250422 — Filing Date (The proxy statement was filed on this date.)
Key Players & Entities
- MoonLake Immunotherapeutics (company) — Registrant
- Helix Acquisition Corp (company) — Former company name
- 0001140361-25-014923 (dollar_amount) — Accession Number
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or Definitive Proxy Statement, is used by companies to solicit proxies from shareholders for an upcoming shareholder meeting, providing details on matters to be voted upon.
When is MoonLake Immunotherapeutics' annual meeting scheduled?
The annual meeting is scheduled for June 5, 2025.
What was MoonLake Immunotherapeutics' former name?
MoonLake Immunotherapeutics was formerly known as Helix Acquisition Corp.
What is the SIC code for MoonLake Immunotherapeutics?
The Standard Industrial Classification (SIC) code for MoonLake Immunotherapeutics is 2834, which corresponds to Pharmaceutical Preparations.
Is this a preliminary or definitive proxy statement?
This is a definitive proxy statement, as indicated by the filing type and the checkmark next to 'Definitive Proxy Statement'.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 22, 2025 regarding MoonLake Immunotherapeutics (MLTX).